Highlights
- Avita Medical (AVH) shares jump over 11% following revenue guidance announcement.
- Company projects a 55-65% growth in full-year 2024 commercial revenue.
- Net loss widens due to increased operating expenses.
Avita Medical (ASX:AVH) saw a sharp rise in its share price, gaining 11.6% on Friday after unveiling an optimistic revenue forecast for 2025. The company, known for its innovative wound care solutions, projected commercial revenues between $100 million and $106 million USD ($158.16 million to $167.65 million AUD).
This updated outlook signals a significant growth of 55% to 65% in full-year 2024 revenue, reflecting the increasing demand for its RECELL GO product. Avita Medical (ASX:AVH) has been expanding its market presence, with both new and existing customers contributing to the rise in adoption.
For the latest financial year, commercial revenue reached $64 million USD, representing a 29% increase compared to the previous year. The company attributes this growth to a strong uptake of its technology, which is designed to enhance the healing process for patients with severe burns and other skin injuries.
Despite this impressive revenue expansion, Avita Medical (ASX:AVH) reported a net loss of $61.8 million USD, up from $35.4 million USD in the prior year. The increased losses were attributed to higher operating expenses and lower other income. As the company invests in research, development, and market expansion, these costs have impacted its bottom line.
Looking ahead, Avita Medical (ASX:AVH) remains focused on further commercializing its products and capitalizing on the growing demand for advanced wound care solutions. The strong revenue projections indicate confidence in its market positioning, while the rise in costs highlights the investments being made to support future growth.
With its latest revenue guidance and the expanding adoption of RECELL GO, Avita Medical (AVH) continues to capture investor attention. The recent surge in share price reflects market optimism surrounding its growth trajectory and potential for long-term success in the healthcare sector.